Postoperative serum osteopontin level is a novel monitor for treatment response and tumor recurrence after resection of hepatitis B-related hepatocellular carcinoma

Annals of Surgical Oncology

Volumn 20, Issue 3, 2013, Pages 929-937

  Zhou, Chuang ^a,b   Zhou, Hai Jun ^a,b   Zhang, Xiao Fei ^a,b   Lou, Li Li ^a,b   Ye, Qing Hai ^a,b   Zheng, Yan ^a   Wang, Ji ^a,b   Zhu, Hai Tao ^a,b   Dong, Qiong Zhu ^a   Jia, Hu Liang ^a,b   Zhu, Wen Wei ^a,b   Guo, Lei ^a,b   Zhao, Yue ^a   Gao, Dong Mei ^a,b   Qin, Lun Xiu ^a,b  

^a FUDAN UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; OSTEOPONTIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; TREATMENT RESPONSE; TUMOR RECURRENCE;

ALPHA-FETOPROTEINS; C-REACTIVE PROTEIN; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OSTEOPONTIN; POSTOPERATIVE PERIOD; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84875226955     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2749-9     Document Type: Article

References (27)

1. A Jemal F Bray MM Center J Ferlay E Ward D Forman 2011 Global cancer statistics CA Cancer J Clin. 61 69 90 21296855 10.3322/caac.20107
2. HB El-Serag 2011 Hepatocellular carcinoma N Engl J Med. 365 1118 1127 21992124 10.1056/NEJMra1001683 1:CAS:528:DC%2BC3MXht1WqtrnL
3. J Bruix JM Llovet 2009 Major achievements in hepatocellular carcinoma Lancet. 373 614 616 19231618 10.1016/S0140-6736(09)60381-0
4. NN Rahbari A Mehrabi NM Mollberg SA Muller M Koch MW Buchler, et al. 2011 Hepatocellular carcinoma: current management and perspectives for the future Ann Surg. 253 453 469 21263310 10.1097/SLA.0b013e31820d944f
5. B Minguez Y Hoshida A Villanueva S Toffanin L Cabellos S Thung, et al. 2011 Gene-expression signature of vascular invasion in hepatocellular carcinoma J Hepatol. 55 1325 1331 21703203 10.1016/j.jhep.2011.02.034 1:CAS:528: DC%2BC3MXhsV2mt7zN
6. Q Gao SJ Qiu J Fan J Zhou XY Wang YS Xiao, et al. 2007 Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection J Clin Oncol. 25 2586 2593 17577038 10.1200/JCO.2006.09.4565
7. HC Sun W Zhang LX Qin BH Zhang QH Ye L Wang, et al. 2007 Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma J Hepatol. 47 684 690 17854945 10.1016/j.jhep.2007.06. 019 1:CAS:528:DC%2BD2sXhtFeiur7O
8. HL Jia QH Ye LX Qin A Budhu M Forgues Y Chen, et al. 2007 Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma Clin Cancer Res. 13 1133 1139 17317821 10.1158/1078-0432.CCR-06-1025 1:CAS:528:DC%2BD2sXhvF2hsLs%3D
9. G Malaguarnera M Giordano I Paladina M Berretta A Cappellani M Malaguarnera 2010 Serum markers of hepatocellular carcinoma Dig Dis Sci. 55 2744 2755 20339916 10.1007/s10620-010-1184-7 1:CAS:528:DC%2BC3cXhtF2lurvP
10. PC Mack MW Redman K Chansky SK Williamson NC Farneth PJ Lara, et al. 2008 Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003 J Clin Oncol. 26 4771 4776 18779603 10.1200/JCO.2008.17.0662 1:CAS:528:DC%2BD1cXhtlSqsb7I
11. SK Ramaiah S Rittling 2008 Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer Toxicol Sci. 103 4 13 17890765 10.1093/toxsci/kfm246 1:CAS:528:DC%2BD1cXksF2lsrc%3D
12. PH Anborgh JC Mutrie AB Tuck AF Chambers 2010 Role of the metastasis-promoting protein osteopontin in the tumour microenvironment J Cell Mol Med. 14 2037 2044 20597997 10.1111/j.1582-4934.2010.01115.x 1:CAS:528:DC%2BC3cXhsVahurbJ
13. QH Ye LX Qin M Forgues P He JW Kim AC Peng, et al. 2003 Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning Nat Med. 9 416 423 12640447 10.1038/nm843 1:CAS:528:DC%2BD3sXisVOmu7o%3D
14. H Zhang QH Ye N Ren L Zhao YF Wang X Wu, et al. 2006 The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma J Cancer Res Clin Oncol. 132 709 717 16786357 10.1007/s00432-006-0119-3 1:CAS:528:DC%2BD28XptVajs78%3D
15. H Huang XF Zhang HJ Zhou YH Xue QZ Dong QH Ye, et al. 2010 Expression and prognostic significance of osteopontin and caspase-3 in hepatocellular carcinoma patients after curative resection Cancer Sci. 101 1314 1319 20345480 10.1111/j.1349-7006.2010.01524.x 1:CAS:528:DC%2BC3cXmsF2qu7s%3D
16. HC Sun PY Zhuang LX Qin QH Ye L Wang N Ren, et al. 2007 Incidence and prognostic values of lymph node metastasis in operable hepatocellular carcinoma and evaluation of routine complete lymphadenectomy J Surg Oncol. 96 37 45 17345597 10.1002/jso.20772
17. H Zhou H Huang J Shi Y Zhao Q Dong H Jia, et al. 2010 Prognostic value of interleukin 2 and interleukin 15 in peritumoral hepatic tissues for patients with hepatitis B-related hepatocellular carcinoma after curative resection Gut. 59 1699 1708 20940284 10.1136/gut.2010.218404
18. H Xie J Song R Du K Liu J Wang H Tang, et al. 2007 Prognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinoma Dig Liver Dis. 39 167 172 17161983 10.1016/j.dld.2006.10.015 1:CAS:528:DC%2BD2sXktFWgs78%3D
19. XR Yang Y Xu GM Shi J Fan J Zhou Y Ji, et al. 2008 Cytokeratin 10 and cytokeratin 19:predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection Clin Cancer Res. 14 3850 3859 18559605 10.1158/1078-0432.CCR-07-4338 1:CAS:528:DC%2BD1cXntlWrtrc%3D
20. BS Sun QZ Dong QH Ye HJ Sun HL Jia XQ Zhu, et al. 2008 Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma Hepatology. 48 1834 1842 18972404 10.1002/hep.22531 1:CAS:528:DC%2BD1cXhsFamsrfJ
21. YH Xue XF Zhang QZ Dong J Sun C Dai HJ Zhou, et al. 2010 Thrombin is a therapeutic target for metastatic osteopontin-positive hepatocellular carcinoma Hepatology. 52 2012 2022 20890897 10.1002/hep.23942 1:CAS:528:DC%2BC3cXhs1WltLjN
22. J Sun HM Xu HJ Zhou QZ Dong Y Zhao LY Fu, et al. 2010 The prognostic significance of preoperative plasma levels of osteopontin in patients with TNM stage-I of hepatocellular carcinoma J Cancer Res Clin Oncol. 136 1 7 19593583 10.1007/s00432-009-0629-x 1:CAS:528:DC%2BD1MXhsVertrjL
23. BK Cui CQ Zhang Y Zhang YF Yuan YQ Zhang, et al. 2006 Osteopontin as a potential biomarker of metastasis and recurrence for hepatocellular carcinoma Ai Zheng. 25 876 879 16831281 1:CAS:528:DC%2BD1cXhvVyrtw%3D%3D
24. S Shang A Plymoth S Ge Z Feng HR Rosen S Sangrajrang, et al. 2012 Identification of osteopontin as a novel marker for early hepatocellular carcinoma Hepatology. 55 483 490 21953299 10.1002/hep.24703 1:CAS:528: DC%2BC38Xht1yqtb8%3D
25. J Kim SS Ki SD Lee CJ Han YC Kim SH Park, et al. 2006 Elevated plasma osteopontin levels in patients with hepatocellular carcinoma Am J Gastroenterol. 101 2051 2059 16848813 10.1111/j.1572-0241.2006.00679.x 1:CAS:528: DC%2BD28XhtVyisLzI
26. JD Blasberg HI Pass CM Goparaju RM Flores S Lee JS Donington 2010 Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer J Clin Oncol. 28 936 941 20085934 10.1200/JCO.2009.25.5711 1:CAS:528:DC%2BC3cXktF2lsbc%3D
27. D Petrik PW Lavori H Cao Y Zhu P Wong E Christofferson, et al. 2006 Plasma osteopontin is an independent prognostic marker for head and neck cancers J Clin Oncol. 24 5291 5297 17114663 10.1200/JCO.2006.06.8627 1:CAS:528:DC%2BD28XhtlemurbF